[Ceftazidime: antibacterial activity and clinical efficacy in obstetrics and gynecology].
Ceftazidime ( CAZ ) exhibited in vitro activity greater than cefoperazone, cefotiam, cefmetazole and cefazolin and almost equal to cefotaxime (CTX), ceftizoxime (CZX) and latamoxef ( LMOX ) against E. coli and K. pneumoniae isolated from obstetrical or gynecological infections excluding urinary tract infections. This drug demonstrated less activity than other 6 cephems against B. fragilis. Against anaerobic Gram-positive cocci, it showed less activity than other cephems. CAZ was administered to 11 patients with obstetrical and gynecological infections. The clinical results of this drug were as follows; excellent in each 1 case of parametritis , wound infection and BARTHOLIN's abscess, good in 7 cases including 1 of puerperal fever, 2 of intrauterine infection and 4 of adnexitis, and poor in 1 cases of adnexitis. No side effects or haematobiochemical abnormalities were observed throughout this trial.
D000328:Adult; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002442:Ceftazidime; D002511:Cephalosporins / Q000494:pharmacology / Q000627:therapeutic use*; D002585:Cesarean Section; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D008875:Middle Aged; D011247:Pregnancy; D011645:Puerperal Infection / Q000188:drug therapy
D002511:Cephalosporins; D002442:Ceftazidime